Aier Ophthalmology intends to acquire Europe's largest ophthalmic medical institution, establishing its position as a gl
Aier Ophthalmology intends to acquire Europe's largest ophthalmic medical institution, establishing its position as a global leader in ophthalmology Today, Aier Ophthalmology announced that the company intends to launch a voluntary takeover offer to shareholders holding 100% of the shares of Cl铆nica Baviera, S.A. through Aier International (Europe) Co., Ltd., which is indirectly wholly owned. According to the "irrevocable equity transfer commitment" between Aier International (Europe) and the six shareholders who hold a total of 69.353% of the equity of the target company, the latter will transfer its 59.353% equity interest to Aier.
Cl铆nica Baviera, S.A. is Europe's largest chain of ophthalmic medical listed institutions, with a history of decades, nearly 300 ophthalmologists and optometrists, including the founder Dr. Julio Baviera, a group of key doctors, including the founder Dr. Julio Baviera, enjoy a high reputation in the European ophthalmology community.
Cl铆nica Baviera, S.A. has a wide influence in European ophthalmology and even the entire medical field, and currently has a total of 76 ophthalmic medical institutions in Spain, Germany, Italy and other countries. Professor Tang Shibo, Dean and Doctoral Supervisor of Aier Ophthalmology College of Central South University, and General Director of Aier Eye Hospital Group, believes that as a developed global economic region, European patients have always had a "high" demand for medical services. At the same time, as one of the most developed regions in the world in terms of medical technology, the European medical industry has always been known for its academic rigor, technical specifications and high-end services.
Cl铆nica Baviera, S.A. is a prestigious chain of medical institutions in the field of ophthalmology, with a global leader in medical technology and service quality, and is a prestigious representative of high-end ophthalmic care in Europe. Through the introduction of an international team of experts from Europe, it will promote the rapid development of high-end services and meet the growing demand for high-end medical services.
Wu Shijun, secretary of the board of directors of Aier Ophthalmology, said that Aier Ophthalmology and Cl铆nica Baviera have similar cultural concepts, and the two parties have conducted long-term and smooth communication and exchanges, highly recognized each other's vision and strategy, and the core team and doctors will continue to remain after the merger, which has laid a solid foundation for smooth integration and growth. At the same time, the acquisition is not aimed at delisting, and is expected to become the only ophthalmology institution in the world to be listed in both China and overseas, and will work together to create a global industry model for the benefit of global eye disease patients.
Chen Bang, chairman of Aier Ophthalmology, said that this transaction is unprecedented in the international ophthalmology community in terms of volume and layout, and is an important milestone for the development of Aier Ophthalmology, a big step in practicing the concept of "sharing global ophthalmology wisdom", and a new platform for building an eye health ecosystem. Aier will occupy a leading position in Europe in one fell swoop, build a strategic pattern of global coordinated development, accelerate the global integration of clinical, scientific research and human resources, build a high-level world-class ophthalmology platform, and greatly enhance its comprehensive competitiveness.
Senior experts in the industry said that Aier Ophthalmology and Cl铆nica Baviera are the largest ophthalmology medical institutions in China and Europe respectively, and this acquisition is another major move to promote the globalization strategy after Aier Ophthalmology has successfully acquired first-class ophthalmology centers in Hong Kong and the United States, which is conducive to the company's mastery of the most cutting-edge ophthalmology technology and service system, and will undoubtedly further expand Aier's leading position in the global ophthalmology industry.